SEC Comment Letter 0000000000-23-003355 to Crinetics Pharmaceuticals, Inc. (CRNX) (CIK 0001658247) (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX) (CIK 0001658247)
Date: April 4, 2023 · CIK: 0001658247 · Accession: 0000000000-23-003355
AI Filing Summary & Sentiment
File numbers found in text: 001-38583
Letter
United States securities and exchange commission logo April 4, 2023 Marc J.S. Wilson Chief Financial Officer Crinetics Pharmaceuticals, Inc. 10222 Barnes Canyon Road Bldg. #2 San Diego, California 92121 Re:Crinetics Pharmaceuticals, Inc. Form 10-K for Fiscal Year Ended December 31, 2021 Filed March 30, 2022 File No. 001-38583 Dear Marc J.S. Wilson: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
April 4, 2023
Marc J.S. Wilson
Chief Financial Officer
Crinetics Pharmaceuticals, Inc.
10222 Barnes Canyon Road
Bldg. #2
San Diego, California 92121
Re:Crinetics Pharmaceuticals, Inc.
Form 10-K for Fiscal Year Ended December 31, 2021
Filed March 30, 2022
File No. 001-38583
Dear Marc J.S. Wilson:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences